Chief Accounting Officer Louise Kooij to Depart NewAmsterdam Pharma
NAMS sits 77% above its 52-week low of $16.785.
Summary
NewAmsterdam Pharma announced that Chief Accounting Officer Louise Kooij will depart the company effective August 31, 2026, with a separation agreement in place.
Key Events · Executive and Board Changes · NAMS
-
Chief Accounting Officer Departure
Louise Kooij will step down as Chief Accounting Officer effective August 31, 2026, by mutual agreement.
-
Separation Agreement Terms
Ms. Kooij will receive a lump sum equal to 12 months of her base salary, a pro-rated 2026 annual cash bonus, and accrued holiday/vacation days.
-
Equity Vesting Extended
Vesting of outstanding stock options and restricted stock units (RSUs) will be extended through January 10, 2027, with an exercise period until February 10, 2027.
-
Restrictive Covenants
The separation agreement includes confidentiality, non-compete, non-disparagement covenants, and a release of claims.
Analysis · NAMS · Life Sciences
The departure of a Chief Accounting Officer, even if amicable and planned, introduces a transition period for a key financial role. The company has outlined a standard separation package, including a lump sum, pro-rated bonus, and extended equity vesting, which aims to ensure an orderly transition and adherence to restrictive covenants. Investors will monitor the appointment of a successor and any potential impact on financial reporting.
At the time of this filing, NAMS was trading at $29.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $16.79 to $42.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.